Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Durvalumab [USAN:INN]
RN: 1428935-60-7
UNII: 28X28X9OKV

Note

  • Targets PD-L1 protein; in phase 1 clinical trials (2014).

    NCI: A Fc optimized monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; B7 homolog 1; B7H1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, durvalumab binds to PD-L1, thereby blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells. This may reverse T-cell inactivation and activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against PD-L1-expressing tumor cells. PD-L1, a member of the B7 protein superfamily, is overexpressed on certain tumor cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. The Fc region of durvalumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). (NCI Thesaurus)

Molecular Formula

  • Unspecified
 

Classification Code

  • Antineoplastic Agents
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Durvalumab [USAN:INN]
  • MEDI-4736

Synonyms

  • Durvalumab
  • Imfinzi
  • Immunoglobulin G1, anti-(human cd antigen cd274) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 kappa-chain, dimer
  • Immunoglobulin G1, anti-(human protein B7-H1) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 kappa-chain, dimer
  • MEDI 4736
  • MEDI4736
  • UNII-28X28X9OKV

Registry Numbers

CAS Registry Number

  • 1428935-60-7

FDA UNII

  • 28X28X9OKV

Other Registry Number

  • 1493766-03-2

System Generated Number

  • 1428935607